一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Sacituzumab tirumotecan；Pembrolizumab；Cisplatin；Pemetrexed；Gemcitabine；Carboplatin；Paclitaxel；Rescue medication，当前状态为招募中。登记地点显示中国北京、福州、广州、郑州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sacituzumab tirumotecan；Pembrolizumab；Cisplatin；Pemetrexed；Gemcitabine；Carboplatin；Paclitaxel；Rescue medication · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer hospital-Thoracic Surgery department I ( Site 1301) · 北京
- Beijing Peking Union Medical College Hospital-Thoracic surgery department ( Site 1302) · 北京
- Peking University People's Hospital ( Site 1300) · 北京
- Fujian Cancer Hospital-oncology department ( Site 1314) · 福州
- The First Affiliated Hospital of Guangzhou Medical University-thoracic surgery department ( Site 1320) · 广州
- Southern Medical University Nanfang Hospital-Thoracic surgery department ( Site 1313) · 广州
- Henan Cancer Hospital-henan cancer hospital ( Site 1316) · 郑州
- Union Hospital Tongji Medical College Huazhong University of Science and Technology-Thoracic Surgery ( Site 1306) · 武汉
- Hubei Cancer Hospital ( Site 1308) · 武汉
- Xiangya Hospital Central South University-Thoracic surgery ( Site 1311) · 长沙
- Hunan Cancer Hospital ( Site 1312) · 长沙
- Nanjing First Hospital ( Site 1310) · 南京
- The First Affiliated Hospital of Soochow University-Thoracic Surgery Department ( Site 1318) · 苏州
- The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 1330) · 南昌
- The First Hospital of Jilin University ( Site 1324) · 长春
- The Second Affiliated Hospital of Air Force Medical University ( Site 1332) · 西安
- Shandong Cancer Hospital ( Site 1321) · 济南
- Zhongshan Hospital Fudan University ( Site 1325) · 上海
- Shanghai Pulmonary Hospital-Thoracic Surgery department ( Site 1304) · 上海
- Sichuan Cancer hospital. ( Site 1327) · 成都
- The Second People's Hospital of Neijiang ( Site 1322) · 内江
- Yunnan Province Cancer Hospital ( Site 1315) · 昆明
- The first Affiliated Hospital, Zhejiang University School of-Thoracic Cardiovascular Surgery Ward ( Site 1303) · 杭州
- Zhejiang Cancer Hospital ( Site 1309) · 杭州
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 1328) · 杭州
- Taizhou Hospital of Zhejiang Province ( Site 1329) · 临海
- Ningbo No. 2 Hospital ( Site 1305) · 宁波
公开的入选条件
- * Has histological or cytological confirmation of squamous or nonsquamous non-small cell lung cancer (NSCLC), resectable clinical Stage II, IIIA or IIIB (with nodal involvement \[N2\]) per AJCC eighth edition guidelines
- * Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy
- * Is able to undergo surgery based on opinion of investigator after consultation with surgeon
- * Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy
- * Applies to screening for the adjuvant period only, before randomization: Has not achieved pathological complete response (pCR) at surgery by local review of pathology.
- * Applies to screening for the adjuvant period only, before randomization: Tumor tissue sample from surgical resection has been provided for determination of programmed cell death ligand 1 (PD-L1) and trophoblast cell surface antigen 2 (TROP2) status by centra
- * Applies to screening for the adjuvant period only, before randomization: Confirmed to be disease-free based on re-baseline radiological assessment as documented by contrast enhanced chest/abdomen/pelvis computed tomography (CT) (or magnetic resonance imaging
- * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06312137；登记信息更新于 2026-09-17。